Anti-inflammatory and anticancer effects of flavonol glycosides from Diplotaxis harra through GSK3β regulation in intestinal cells
Open Access
- 22 September 2016
- journal article
- research article
- Published by Taylor & Francis Ltd in Pharmaceutical Biology
- Vol. 55 (1), 124-131
- https://doi.org/10.1080/13880209.2016.1230877
Abstract
Context and objective: Diplotaxis harra (Forssk.) Boiss. (Brassicaceae) is traditionally used as an antidiabetic, anti-inflammatory or anticancer agent. In these pathologies, the glycogen synthase kinase 3 β (GSK3β) is overactivated and represents an interesting therapeutic target. Several flavonoids can inhibit GSK3β and the purpose of this study was to search for the compounds in Diplotaxis harra which are able to modulate GSK3β. Materials and methods: Methanol extracts from D. harra flowers were prepared and the bio-guided fractionation of their active compounds was performed using inflammatory [protease-activated receptor 2 (PAR2)-stimulated IEC6 cells] and cancer (human Caco-2 cell line) intestinal cells. 50–100 μg/mL of fractions or compounds purified by HPLC were incubated with cells whose inhibited form of GSK3β (Pser9 GSK3β) and survival were analyzed by Western blot at 1 h and colorimetric assay at 24 h, respectively. LC-UV-MS profiles and MS-MS spectra were used for the characterization of extracts and flavonoids-enriched fractions, and the identification of pure flavonoids was achieved by MS and NMR analysis. Results: The methanol extract from D. harra flowers and its flavonoid-enriched fraction inhibit GSK3β in PAR2-stimulated IEC6 cells. GSK3β inhibition by the flavonoid-enriched D. harra fraction was dependent on PKC activation. The flavonoid-enriched D. harra fraction and its purified compound isorhamnetin-3,7-di-O-glucoside induced a 20% decrease of PAR2-stimulated IEC6 and Caco-2 cell survival. Importantly, normal cells (non-stimulated IEC6 cells) were spared by these treatments. Conclusion: This work indicates that flavonoids from D. harra display cytotoxic activity against inflammatory and cancer intestinal cells which could depend on GSK3β inhibition.Keywords
Funding Information
- This work was supported by the European Research Council Starting Grant (ERC_2012_StG_20111109)
- Ligue Régionale contre le Cancer (2013 Aude Comity)
- Ministry of Higher Education and Scientific Research of Tunisia
- PHC Utique cooperation (N°CMCU12G0821)
- Association de recherche contre le cancer (N°SFI20121205496)
This publication has 32 references indexed in Scilit:
- Chemoprevention of Intestinal Polyps in ApcMin/+ Mice Fed with Western or Balanced Diets by Drinking Annurca Apple Polyphenol ExtractCancer Prevention Research, 2011
- Citrus Flavonoids Luteolin, Apigenin, and Quercetin Inhibit Glycogen Synthase Kinase-3β Enzymatic Activity by Lowering the Interaction Energy Within the Binding CavityJournal of Medicinal Food, 2011
- Molecular mechanisms for chemoprevention of colorectal cancer by natural dietary compoundsMolecular Nutrition & Food Research, 2010
- Flavonoids from Halostachys caspica and Their Antimicrobial and Antioxidant ActivitiesMolecules, 2010
- Glycogen Synthase Kinase 3 (GSK-3) influences epithelial barrier function by regulating Occludin, Claudin-1 and E-cadherin expressionBiochemical and Biophysical Research Communications, 2010
- Flavonoids, proanthocyanidins, and the risk of stomach cancerCancer Causes & Control, 2010
- Deregulated GSK3 Sustains Gastrointestinal Cancer Cells Survival by Modulating Human Telomerase Reverse Transcriptase and TelomeraseClinical Cancer Research, 2009
- Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrenceWorld Journal of Gastroenterology, 2008
- Reciprocal Targeting of Hath1 and β-Catenin by Wnt Glycogen Synthase Kinase 3β in Human Colon CancerGastroenterology, 2007
- Neurotensin Phosphorylates GSK-3α/β through the Activation of PKC in Human Colon Cancer CellsNeoplasia, 2006